| Name | Title | Contact Details |
|---|
Caris Life Sciences® (Caris) is a molecular science company developing and delivering technologies to revolutionize healthcare. The Company`s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers improve outcomes and save lives. Caris is also advancing precision medicine through advanced artificial intelligence (AI) and machine learning algorithms. Leveraging the Company`s proprietary AI analytics engine, DEAN™, across its extensive catalog of molecular intelligence and clinical outcomes data, Caris is actively developing a better understanding of the molecular mechanisms of cancer in ways never before possible. This information provides an unmatched resource to help physicians better identify and predict patient response to therapy, as well as support researchers and biopharmaceutical companies derive unique insights for research development, clinical trials and target identification. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets.
Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what`s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.
ABR--Affinity BioReagents is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.